Cargando…

Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression

BACKGROUND: Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Domowicz, Miriam S., Chan, Wen-Ching, Claudio-Vázquez, Patricia, Gonzalez, Tatiana, Schwartz, Nancy B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576919/
https://www.ncbi.nlm.nih.gov/pubmed/34749772
http://dx.doi.org/10.1186/s12974-021-02302-z
_version_ 1784595974688079872
author Domowicz, Miriam S.
Chan, Wen-Ching
Claudio-Vázquez, Patricia
Gonzalez, Tatiana
Schwartz, Nancy B.
author_facet Domowicz, Miriam S.
Chan, Wen-Ching
Claudio-Vázquez, Patricia
Gonzalez, Tatiana
Schwartz, Nancy B.
author_sort Domowicz, Miriam S.
collection PubMed
description BACKGROUND: Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound neurodegeneration, but the relationship of the various genes’ function to a single biological process is not obvious. In this study, we used a well-characterized mouse model of classical late infantile NCL (cLINCL) in which the tripeptidyl peptidase 1 (Tpp1) gene is disrupted by gene targeting, resulting in loss of detectable TPP1 activity and leading to progressive neurological phenotypes including ataxia, increased motor deficiency, and early death. METHODS: In order to identify genes and pathways that may contribute to progression of the neurodegenerative process, we analyzed forebrain/midbrain and cerebellar transcriptional differences at 1, 2, 3 and 4 months of age in control and TPP1-deficient mice by global RNA-sequencing. RESULTS: Progressive neurodegenerative inflammatory responses involving microglia, astrocytes and endothelial cells were observed, accompanied by activation of leukocyte extravasation signals and upregulation of nitric oxide production and reactive oxygen species. Several astrocytic (i.e., Gfap, C4b, Osmr, Serpina3n) and microglial (i.e., Ctss, Itgb2, Itgax, Lyz2) genes were identified as strong markers for assessing disease progression as they showed increased levels of expression in vivo over time. Furthermore, transient increased expression of choroid plexus genes was observed at 2 months in the lateral and fourth ventricle, highlighting an early role for the choroid plexus and cerebrospinal fluid in the disease pathology. Based on these gene expression changes, we concluded that neuroinflammation starts, for the most part, after 2 months in the Tpp1(−/−) brain and that activation of microglia and astrocytes occur more rapidly in cerebellum than in the rest of the brain; confirming increased severity of inflammation in this region. CONCLUSIONS: These findings have led to a better understanding of cLINCL pathological onset and progression, which may aid in development of future therapeutic treatments for this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02302-z.
format Online
Article
Text
id pubmed-8576919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85769192021-11-10 Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression Domowicz, Miriam S. Chan, Wen-Ching Claudio-Vázquez, Patricia Gonzalez, Tatiana Schwartz, Nancy B. J Neuroinflammation Research BACKGROUND: Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound neurodegeneration, but the relationship of the various genes’ function to a single biological process is not obvious. In this study, we used a well-characterized mouse model of classical late infantile NCL (cLINCL) in which the tripeptidyl peptidase 1 (Tpp1) gene is disrupted by gene targeting, resulting in loss of detectable TPP1 activity and leading to progressive neurological phenotypes including ataxia, increased motor deficiency, and early death. METHODS: In order to identify genes and pathways that may contribute to progression of the neurodegenerative process, we analyzed forebrain/midbrain and cerebellar transcriptional differences at 1, 2, 3 and 4 months of age in control and TPP1-deficient mice by global RNA-sequencing. RESULTS: Progressive neurodegenerative inflammatory responses involving microglia, astrocytes and endothelial cells were observed, accompanied by activation of leukocyte extravasation signals and upregulation of nitric oxide production and reactive oxygen species. Several astrocytic (i.e., Gfap, C4b, Osmr, Serpina3n) and microglial (i.e., Ctss, Itgb2, Itgax, Lyz2) genes were identified as strong markers for assessing disease progression as they showed increased levels of expression in vivo over time. Furthermore, transient increased expression of choroid plexus genes was observed at 2 months in the lateral and fourth ventricle, highlighting an early role for the choroid plexus and cerebrospinal fluid in the disease pathology. Based on these gene expression changes, we concluded that neuroinflammation starts, for the most part, after 2 months in the Tpp1(−/−) brain and that activation of microglia and astrocytes occur more rapidly in cerebellum than in the rest of the brain; confirming increased severity of inflammation in this region. CONCLUSIONS: These findings have led to a better understanding of cLINCL pathological onset and progression, which may aid in development of future therapeutic treatments for this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02302-z. BioMed Central 2021-11-08 /pmc/articles/PMC8576919/ /pubmed/34749772 http://dx.doi.org/10.1186/s12974-021-02302-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Domowicz, Miriam S.
Chan, Wen-Ching
Claudio-Vázquez, Patricia
Gonzalez, Tatiana
Schwartz, Nancy B.
Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title_full Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title_fullStr Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title_full_unstemmed Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title_short Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
title_sort brain transcriptome analysis of a cln2 mouse model as a function of disease progression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576919/
https://www.ncbi.nlm.nih.gov/pubmed/34749772
http://dx.doi.org/10.1186/s12974-021-02302-z
work_keys_str_mv AT domowiczmiriams braintranscriptomeanalysisofacln2mousemodelasafunctionofdiseaseprogression
AT chanwenching braintranscriptomeanalysisofacln2mousemodelasafunctionofdiseaseprogression
AT claudiovazquezpatricia braintranscriptomeanalysisofacln2mousemodelasafunctionofdiseaseprogression
AT gonzaleztatiana braintranscriptomeanalysisofacln2mousemodelasafunctionofdiseaseprogression
AT schwartznancyb braintranscriptomeanalysisofacln2mousemodelasafunctionofdiseaseprogression